Products

Dear client,
For better user experience, you need modern browsers that are up-to-date. The version of your browser you are using is out of date; this poses a security risk. Please use another browser.
Thank you for your understanding.

HDIT101

HDIT101 is a humanized monoclonal antibody developed for the treatment of herpes simplex virus (HSV) infections. HDIT101 binds to an HSV-1 and HSV-2 common epitope on glycoprotein B which is indispensable for viral infectivity.

 

A first-in-human study showing the pharmacokinetic, safety and tolerability of HDIT101 was completed (HDIT101 phase 1). At present, two randomized phase II studies are currently ongoing in patients with recurrent HSV-2 positive Herpes genitalis (MATCH-2) and in patients with orolabial HSV-1 infections (MATCH-1), respectively.

 

 

How does HDIT101 work

HDIT101 has a unique dual mechanism of action differentiating it from commonly used antiviral drugs. First, HDIT101 is capable of neutralizing circulating HSV particles, and second it inhibits the direct virus spread to neighboring, non-infected cells (cell-to-cell spread).

 

 

No treatment

  • Herpes simplex viruses recognize and invade healthy epithelial cells
  • Infected cells produce new viruses which can infect neighboring cells
  • Infected cells can be destroyed by the virus and the immune system and this leads to inflamed moist blisters

 

Treatment with HDIT101 antibody

  • HDIT101 binds to free viruses and prevents them from entering healthy cells
  • The antibody blocks the spread of virus from infected cells to surrounding cells
  • HDIT101 limits new outbreaks of  herpes
 logo